Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Agios Pharma (AGIO) Issues Positive Update from Dose-Escalation Portion of AG-120 Phase 1
November 9, 2015 6:05 AM ESTAgios Pharma (NASDAQ: AGIO) announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
"Glioma, cholangiocarcinoma and chondrosarcomas are all extremely difficult-to-treat diseases with limited therapeutic options," said Howard Burris, M.D., Sarah Cannon Research Institute, an investigator for the study. "Today's Phase 1... More
Agios Pharma (AGIO) Posts Wider Q3 Loss
November 5, 2015 8:01 AM ESTAgios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.08), $0.20 worse than the analyst estimate of ($0.88). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $17.21 million.
Cash, cash equivalents and marketable securities as of September 30, 2015 were $408.0 million, compared to $467.4 million as... More
